Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ADVANTAGE

Financiado

Cerrado

ADvanced Validation of A Novel TB Active disease diagnostic to address Global un...

ADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs a European consortium approach Tuberculosis (TB) remains an EU and global healthcare priority resulting in over 1.4 million deaths each year. Despite this and efforts to reduce TB by the EU commission, the WHO and others, a simple, rapid, diagnostic test for ac... ver más

31/03/2019

PROTEINLOGIC LIMIT...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

PROTEINLOGIC LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-03-31

PHC-12-2014: Clinical research for the validatio...

I+D

Cerrada hace 10 años

0% 92% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

PROTEINLOGIC LIMITED

3.03M€ | Lider

BIOSENSIA

551.85K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

mfloDx Adaptable Multiflow Diagnostic Platform to Genetically Ident... 71K€ Cerrado

RAPP-ID Development of RApid Point of Care test Platforms for Infect... 16M€ Cerrado

ARREST-TB Accurate Rapid Robust and Economical diagnostic technoliog... 4M€ Cerrado

BES-2014-071066 TRANSFORMANDO LAS NUEVAS TECNOLOGIAS DE SECUENCIACION EN UNA... Cerrado

PCI2023-143397 Inmunidad, infección e inmunoterapia 100K€ Cerrado

RAPP-ID Development of RApid Point-of-Care test Platforms for Infect... 16M€ Cerrado

Duración del proyecto: 45 meses Fecha Inicio: 2015-06-18
Fecha Fin: 2019-03-31

Líder del proyecto

PROTEINLOGIC LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Tuberculosis (TB) remains an EU and global healthcare priority resulting in over 1.4 million deaths each year. Despite this and efforts to reduce TB by the EU commission, the WHO and others, a simple, rapid, diagnostic test for active tuberculosis (TB) remains elusive. Current diagnostic procedures, while accounting for over $1 bn globally, are poorly selective for active TB, hold risks for healthcare personnel, are slow to yield results and costly. The large potential and high unmet need provide a clear target for commercialisation of a point-of-care (POC) test. Using over 400 clinical samples, ProteinLogic (a UK based diagnostics company) have demonstrated proof of concept for a ground-breaking approach using a panel of protein biomarkers on human serum samples that profile the cell mediated patient response to TB. The objectives of the eight structured work packages within this three year project are to build on the validation of the biomarker TB panel transitioning from a laboratory assay to Biosensia’s novel microfluidic POC platform that has already been successfully proven with a variety of human analytes. Reagents will be developed as part of this project to ensure reduced costs and security of commercial supply. A unique instrument reader plus TB cartridge-based product will be developed to meet EU regulatory standards. The products will be validated in order to confirm analytical and clinical performance, and to provide evidence of major time, cost & performance improvements compared to current TB testing practises. Successful commercialisation will lead to the creation of over 30 new jobs and will stimulate further private investment in each of the companies. In summary, ADVANTAGE has the potential to deliver a disruptive POC TB diagnostic test that can help eradicate the massive TB burden not only in EU but also globally.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores